146 related articles for article (PubMed ID: 37157135)
1. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Johnson ML; Aparasu RR
Pharmacotherapy; 2023 Jun; 43(6):473-484. PubMed ID: 37157135
[TBL] [Abstract][Full Text] [Related]
2. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
[TBL] [Abstract][Full Text] [Related]
3. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis.
Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
Patient Prefer Adherence; 2020; 14():2187-2199. PubMed ID: 33177813
[TBL] [Abstract][Full Text] [Related]
4. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
6. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
Li J; Chikermane SG; Earla JR; Hutton GJ; Aparasu RR
Mult Scler Relat Disord; 2022 Apr; 60():103703. PubMed ID: 35278846
[TBL] [Abstract][Full Text] [Related]
7. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis.
Earla JR; Hutton GJ; Thornton DJ; Chen H; Johnson ML; Aparasu RR
Pharmacotherapy; 2021 May; 41(5):440-450. PubMed ID: 33641232
[TBL] [Abstract][Full Text] [Related]
8. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis.
Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
Explor Res Clin Soc Pharm; 2021 Jun; 2():100021. PubMed ID: 35481133
[TBL] [Abstract][Full Text] [Related]
10. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
Setayeshgar S; Kingwell E; Zhu F; Zhang T; Carruthers R; Marrie RA; Evans C; Tremlett H
Mult Scler Relat Disord; 2019 Jan; 27():364-369. PubMed ID: 30476872
[TBL] [Abstract][Full Text] [Related]
11. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
Desai RJ; Mahesri M; Gagne JJ; Hurley E; Tong A; Chitnis T; Minden S; Spettell CM; Matlin OS; Shrank WH; Choudhry NK
J Manag Care Spec Pharm; 2019 Jan; 25(1):113-121. PubMed ID: 30589630
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
Laplaud DA; Casey R; Barbin L; Debouverie M; De Sèze J; Brassat D; Wiertlewski S; Brochet B; Pelletier J; Vermersch P; Edan G; Lebrun-Frenay C; Clavelou P; Thouvenot E; Camdessanché JP; Tourbah A; Stankoff B; Al Khedr A; Cabre P; Lubetzki C; Papeix C; Berger E; Heinzlef O; Debroucker T; Moreau T; Gout O; Bourre B; Wahab A; Labauge P; Magy L; Defer G; Guennoc AM; Maubeuge N; Labeyrie C; Patry I; Nifle C; Casez O; Michel L; Rollot F; Leray E; Vukusic S; Foucher Y;
Neurology; 2019 Aug; 93(7):e635-e646. PubMed ID: 31300547
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.
Earla JR; Hutton GJ; Thornton JD; Aparasu RR
Mult Scler Relat Disord; 2020 Oct; 45():102334. PubMed ID: 32629400
[TBL] [Abstract][Full Text] [Related]
14. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
Vieira MC; Conway D; Cox GM; Peeples M; Bensimon AG; Macheca M; Herrera V
Curr Med Res Opin; 2020 Feb; 36(2):261-270. PubMed ID: 31694401
[No Abstract] [Full Text] [Related]
15. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Kretzschmar B; Pellkofer H; Weber MS
Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
[TBL] [Abstract][Full Text] [Related]
16. Prescribing of disease modifying agents in older adults with multiple sclerosis.
Talwar A; Earla JR; Hutton GJ; Aparasu RR
Mult Scler Relat Disord; 2022 Jan; 57():103308. PubMed ID: 35158421
[TBL] [Abstract][Full Text] [Related]
17. Persistence to oral disease-modifying therapies in multiple sclerosis patients.
Lattanzi S; Danni M; Taffi R; Cerqua R; Carlini G; Pulcini A; Provinciali L; Silvestrini M
J Neurol; 2017 Nov; 264(11):2325-2329. PubMed ID: 28831550
[TBL] [Abstract][Full Text] [Related]
18. Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
Ng HS; Kingwell E; Zhu F; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler; 2021 Feb; 27(2):239-249. PubMed ID: 32141376
[TBL] [Abstract][Full Text] [Related]
19. Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review.
Yoon EL; Cheong WL
Mult Scler Relat Disord; 2019 Feb; 28():104-108. PubMed ID: 30590239
[No Abstract] [Full Text] [Related]
20. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
